Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

This completed Phase I/II trial tested a new 26-valent pneumococcal conjugate vaccine in 450 people aged 2 months and older. The goal was to check safety and how well the vaccine triggers an immune response compared to existing vaccines. Researchers monitored side effects and ant…